SpectraWAVE has announced the appointment of Jonathan Hill as chief medical officer.
Hill, a globally renowned interventional cardiologist from Royal Brompton Hospital in London (UK), brings extensive expertise in coronary artery disease, complex percutaneous coronary intervention (PCI), intravascular imaging, physiology, cardiovascular innovation, and clinical study design and implementation, the company says in a press release.
“Jonathan is a highly respected clinician and innovator whose leadership will be critical as SpectraWAVE accelerates commercial adoption and advances its clinical evidence strategy both in the USA and worldwide for our expanding product portfolio,” said Eman Namati, chief executive officer of SpectraWAVE. “His experience integrating intravascular imaging and physiology into daily clinical practice, and being at the front lines of medicine with multiple major worldwide clinical studies will strengthen our partnerships with physicians, research groups, and support our commitment to improving outcomes for CAD patients.”
The announcement comes as SpectraWAVE surpasses thousands of commercial HyperVue imaging system cases in cath labs across the USA and achieves multiple clinical study milestones, the press release adds.
The company recently completed enrolment of a 175-patient US clinical workflow study of HyperVue, its DeepOCT and near-infrared spectroscopy (NIRS) intravascular imaging system, with results scheduled to be presented at the 2025 TCT meeting (25–28 October, San Francisco, USA). In addition, SpectraWAVE has initiated a multi-site US study evaluating its upcoming single-angiogram wire-free FFR technology, currently under review by the US Food and Drug Administration (FDA).
“I am honoured to join SpectraWAVE at such a pivotal time,” said Hill. “The company’s approach to combining intravascular imaging and physiology in a comprehensive and easy-to-use form factor is going to transform decision-making in the cath lab. I look forward to collaborating with the incredible team and the global clinical community as we expand the impact of HyperVue and introduce new technologies and clinical indications beyond intravascular imaging.”
